105 related articles for article (PubMed ID: 15516776)
1. Long-term effects of octreotide on pituitary gigantism: its analgesic action on cluster headache.
Otsuka F; Mizobuchi S; Ogura T; Sato K; Yokoyama M; Makino H
Endocr J; 2004 Oct; 51(5):449-52. PubMed ID: 15516776
[TBL] [Abstract][Full Text] [Related]
2. Five-year follow-up of a 13-year-old boy with a pituitary adenoma causing gigantism--effect of octreotide therapy.
Schoof E; Dörr HG; Kiess W; Lüdecke DK; Freitag E; Zindel V; Rascher W; Dötsch J
Horm Res; 2004; 61(4):184-9. PubMed ID: 14739526
[TBL] [Abstract][Full Text] [Related]
3. Complete biochemical control and pituitary adenoma disappearance in a child with gigantism: efficacy of octreotide therapy.
Ciresi A; Amato MC; Galluzzo A; Giordano C
J Endocrinol Invest; 2011 Feb; 34(2):162-3. PubMed ID: 21502798
[No Abstract] [Full Text] [Related]
4. Long-acting peptidomimergic control of gigantism caused by pituitary acidophilic stem cell adenoma.
Maheshwari HG; Prezant TR; Herman-Bonert V; Shahinian H; Kovacs K; Melmed S
J Clin Endocrinol Metab; 2000 Sep; 85(9):3409-16. PubMed ID: 10999842
[TBL] [Abstract][Full Text] [Related]
5. Case study of a 15-year-old boy with McCune-Albright syndrome combined with pituitary gigantism: effect of octreotide-long acting release (LAR) and cabergoline therapy.
Tajima T; Tsubaki J; Ishizu K; Jo W; Ishi N; Fujieda K
Endocr J; 2008 Jul; 55(3):595-9. PubMed ID: 18445999
[TBL] [Abstract][Full Text] [Related]
6. Effect of preoperative use of long-acting octreotide on growth hormone secreting pituitary adenoma and transsphenoidal surgery.
Yin J; Su CB; Xu ZQ; Yang Y; Ma WB; Tao W; Yang Z; Xia XW
Chin Med Sci J; 2005 Mar; 20(1):23-6. PubMed ID: 15844307
[TBL] [Abstract][Full Text] [Related]
7. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
Laczi F; Magony S; Julesz J
Orv Hetil; 2002 May; 143(19 Suppl):1062-6. PubMed ID: 12063861
[TBL] [Abstract][Full Text] [Related]
8. Pituitary gigantism caused by growth hormone excess from infancy.
Gelber SJ; Heffez DS; Donohoue PA
J Pediatr; 1992 Jun; 120(6):931-4. PubMed ID: 1593354
[TBL] [Abstract][Full Text] [Related]
9. Analgesic effect of octreotide in headache associated with acromegaly is not mediated by opioid mechanisms. Case report.
Pascual J; Freijanes J; Berciano J; Pesquera C
Pain; 1991 Dec; 47(3):341-344. PubMed ID: 1664509
[TBL] [Abstract][Full Text] [Related]
10. Eight-year follow-up of a child with a GH/prolactin-secreting adenoma: efficacy of pegvisomant therapy.
Bergamaschi S; Ronchi CL; Giavoli C; Ferrante E; Verrua E; Ferrari DI; Lania A; Rusconi R; Spada A; Beck-Peccoz P
Horm Res Paediatr; 2010; 73(1):74-9. PubMed ID: 20190543
[TBL] [Abstract][Full Text] [Related]
11. Remarkable Shrinkage of a Growth Hormone (GH)-secreting Macroadenoma Induced by Somatostatin Analogue Administration: A Case Report and Literature Review.
Kurahashi K; Endo I; Kondo T; Morimoto K; Yoshida S; Kuroda A; Aihara KI; Matsuhisa M; Nakajima K; Mizobuchi Y; Nagahiro S; Abe M; Fukumoto S
Intern Med; 2017 Sep; 56(18):2455-2461. PubMed ID: 28824054
[TBL] [Abstract][Full Text] [Related]
12. Short-term preoperative octreotide treatment for TSH-secreting pituitary adenoma.
Fukuhara N; Horiguchi K; Nishioka H; Suzuki H; Takeshita A; Takeuchi Y; Inoshita N; Yamada S
Endocr J; 2015; 62(1):21-7. PubMed ID: 25273395
[TBL] [Abstract][Full Text] [Related]
13. [Effect of long-term treatment with octreotide-lar in a TSH-secreting pituitary macroadenoma and secondary hyperthyroidism].
Del Monte P; Bernasconi D; Ruelle A; Marugo A; Marugo M; Torre R
Minerva Endocrinol; 2005 Jun; 30(2):95-9. PubMed ID: 15988405
[TBL] [Abstract][Full Text] [Related]
14. Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro.
de Bruin TW; Kwekkeboom DJ; Van't Verlaat JW; Reubi JC; Krenning EP; Lamberts SW; Croughs RJ
J Clin Endocrinol Metab; 1992 Nov; 75(5):1310-7. PubMed ID: 1430093
[TBL] [Abstract][Full Text] [Related]
15. Headache in acromegaly: dramatic improvement with the somatostatin analogue SMS 201-995.
Musolino NR; Marino Júnior R; Bronstein MD
Clin J Pain; 1990 Sep; 6(3):243-5. PubMed ID: 2135020
[TBL] [Abstract][Full Text] [Related]
16. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
Jenkins PJ; Emery M; Howling SJ; Evanson J; Besser GM; Monson JP
Horm Res; 2004; 62(5):227-32. PubMed ID: 15477693
[TBL] [Abstract][Full Text] [Related]
17. [Experience in treating acromegalic patients with long-acting octreotide].
Szücs N; Mészáros J; Czirják S; Mondok A; Varga I; Gláz E
Orv Hetil; 2002 May; 143(19 Suppl):1066-70. PubMed ID: 12063862
[TBL] [Abstract][Full Text] [Related]
18. Chronic cluster headache and the pituitary gland.
De Pue A; Lutin B; Paemeleire K
J Headache Pain; 2016; 17():23. PubMed ID: 26969187
[TBL] [Abstract][Full Text] [Related]
19. Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl.
Rix M; Laurberg P; Hoejberg AS; Brock-Jacobsen B
Eur J Endocrinol; 2005 Aug; 153(2):195-201. PubMed ID: 16061823
[TBL] [Abstract][Full Text] [Related]
20. [Analgesic effect on headaches of octreotide, a somatostatin analogue, in a case of non-functioning pituitary adenoma].
Turpin G; Foubert L; Noel-Wekstein S; Kujas M; De Gennes JL
Presse Med; 1991 Dec; 20(43):2219-20. PubMed ID: 1838161
[No Abstract] [Full Text] [Related]
[Next] [New Search]
